Episode
Case Preview: Hikma v. Amarin | Did Hikma's Sales Pitch Steal Amarin's Patent?
- Podcast
- The High Court Report
- Published
- Apr 19, 2026
- Duration seconds
- 970
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-high-court-report-7304353/episodes/case-preview-hikma-v-amarin-did-hikma-s-sales-pitch-steal-amarin-s-patent/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-high-court-report-7304353/case-preview-hikma-v-amarin-did-hikma-s-sales-pitch-steal-amarin-s-patent.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. | Case No. 24-889 | Docket Link: Here Question Presented: Whether a generic drugmaker that fully carves patented uses from its label actively induces patent infringement through investor press releases and website statements that do not mention, encourage, or instruct the patented use Overview: Generic drugmaker Hikma followed federal skinny-label law but called its product "generic Vascepa" and touted Vascepa's total sales. Brand manufacturer Amarin claims those statements actively induced doctors to prescribe the generic for a patented cardiovascular use worth over $900 million annually. Posture: District court dismissed; Federal Circuit reversed; Supreme Court granted certiorari January 2026. Main Arguments: • Hikma (Petitioner): (1) "Actively" induces requires affirmative steps encouraging infringement — none of Hikma's statements mention or instruct the patented use; (2) Amarin's theory of liability imputes inferences physicians might draw, not active steps Hikma took; (3) The Federal Circuit's decision effectively nullifies the section viii skinny-label pathway Congress created to speed generic competition • Amarin (Respondent): (1) Hikma advertised its generic for "Hypertriglyceridemia" — a category encompassing the patented cardiovascular use — going beyond compliant labeling; (2) Press releases calling the product "generic Vascepa" and touting $919 million to $1.1 billion in total Vascepa sales plausibly encouraged prescribers to use the generic for all of Vascepa's indications; (3) Seven other generic manufacturers selling identical skinny-label products avoided suit by accurately limiting their marketing — proving that compliant speech and section viii coexist Implications: Hikma victory establishes that…